French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position statement from the European Society of Gene Therapy.
Détails
ID Serval
serval:BIB_AA7C8F9CEC50
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position statement from the European Society of Gene Therapy.
Périodique
Journal of Gene Medicine
Collaborateur⸱rice⸱s
European Society of Gene Therapy
ISSN
1099-498X (Print)
ISSN-L
1099-498X
Statut éditorial
Publié
Date de publication
2003
Volume
5
Numéro
1
Pages
82-84
Langue
anglais
Notes
Publication types: Journal ArticlePublication Status: ppublish. Nicole Deglon fait partie de European Society of Gene Therapy. pdf type: SOCIETY COMMUNICATION
Mots-clé
Clinical Trials Data Monitoring Committees, Clinical Trials as Topic, Europe, Genetic Diseases, X-Linked/genetics, Genetic Diseases, X-Linked/therapy, Genetic Therapy/adverse effects, Genetic Therapy/legislation & jurisprudence, Humans, Severe Combined Immunodeficiency/genetics, Severe Combined Immunodeficiency/therapy
Pubmed
Web of science
Création de la notice
13/12/2011 17:04
Dernière modification de la notice
23/11/2023 11:19
Données d'usage
